Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

AMA letter on opioids leaves out recommendations from Senate’s no. 2 Democrat

AMA President Steven Stack, MD, said pain management policies “well-intended but now known to be flawed” have contributed to the increase in abuse of opioid prescription pain relievers

State laws on ‘right-to-try’ experimental drugs backed by new Senate proposal

Legislation would prevent the FDA from restricting or prohibiting access to experimental drugs for a terminal patient in a state with a “right-to-try” law.

Thumbnail

Sen. Durbin urges AMA, others to take action on opioid prescriptions

Durbin spoke with HealthExec about what he’s heard from physicians prescribing opioids, where he feels medical associations have fallen short, and whether federal legislation on prescribing practices will be needed.

Biden pushes for hospitals, providers, scientists to provide access to open data

Vice President Joe Biden spoke at Health Datapalooza in Washington, D.C. this week, emphasizing that his “moonshot” of curing cancer is “a matter of life and death.” 

House passed three bills in the fight against opioids

The House has passed three bills aimed at reducing opioid addiction in an overwhelming 410-1 vote, reports The Hill.

U of C’s $269M hospital expansion, trauma center approved despite criticism of cost

The plan had been criticized in an April by the Illinois Health Facilities and Services Review Board, which said the projected cost was about $18 million too high.

CMS seeks insurers to share ACA successes for June forum

Insurers finding success on the Affordable Care Act’s insurance exchanges are being asked to share what they’ve learned at a June CMS forum.

Will erasing state lines improve healthcare insurance?

The first in a series of videos from the Kaiser Health Network looks at the proposal to allow sales of policies across state lines.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup